Overview
Date:
3:00 pm - 4:00 pm (Seoul)
Time:
28th March 2024, Thursday
Register Now
Please take note that this webinar is conducted in Korean language.
We understand that our webinar timing may not suit your busy schedule. Please feel free to register to get the on-demand recording link once it is ready.
TruSight Oncology 500 family is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers with FFPE samples. The assay supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI).
This webinar provides an overview of TruSight Oncology 500 portfolio including analysis and is targeted at new users of the workflow. We will also introduce TSO500 ctDNA v2 and illumina cfDNA Enrichment for liquid biopsy.
Speakers:
 |
Deresa Lee
Technical Applications Scientist,
Illumina Korea
Deresa graduated from the Sungkyunkwan University in 2012 as a Ph.D in Molecular Genetics. Prior to joining Illumina, she worked in Korea National Institute of Health as a senior researcher and ThermoFisher Scientific as a Field Application Scientist for NGS. Deresa joined Illumina as a Field Applications Scientist in May 2015 and transferred Technical Applications Scientist in May 2018. Since then, she has developed a specialization in providing technical support for the instrumentation queue.
|
 |
Seon Jung Yun
Technical Applications Scientist,
Illumina Korea
Seon Jung graduated from Konkuk University in 2014 majoring in Microbial Biotechnology. In the following years, She worked for DNALink and Macrogen as a researcher regarding statistical analysis of microarray, NIPT and cancer genomics. She joined Illumina as a Technical Applications Scientist in 2022, with a strong desire to learn more about the NGS technology. She has since specialized in providing technical support for the instrument and bioinformatics queue.
|
